Dan Burgess

Dan Burgess is Chairman and CEO of Pulmocide. Mr. Burgess was previously founder, President and CEO of Rempex Pharmaceuticals, Inc., an antibiotic company that was sold to the Medicines Company (now Novartis). Two antibiotics developed by Rempex have since been approved by the FDA. Prior to Rempex he was President and CEO of Mpex Pharmaceuticals, Inc., a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials before it was acquired by Aptalis (now Abbvie). The product was ultimately approved in Europe and Canada. Mr. Burgess is also a Venture Partner with SV Health Investors and is chairman of the board of several public and private biotechnology companies.

Dan is a graduate of Stanford University (AB, Economics) and Harvard Business School (MBA).